Top Clinical Trial Results in Oncology: 2025 Mid-Year Update

The first half of 2025 has delivered a steady stream of practice-informing data across several tumor types. These readouts continue to refine how oncologists sequence therapies, select biomarker-driven regimens, and weigh efficacy against cumulative toxicity. Below is a neutral analysis of the emerging trends, their context, key stakeholder concerns, and what the second half of the year may hold.

Recent Trends in Mid-2025 Trial Data

Several patterns have distinguished this year’s mid-year data presentations and publications:

• Antibody–drug conjugate (ADC) expansion: ADCs targeting novel antigens (e.g., HER3, TROP2, CEACAM5) have reported encouraging response rates in previously treated non-small-cell lung and colorectal cancers, with ongoing scrutiny around interstitial lung disease rates (typically 3–8% across classes).
• Bispecific T-cell engagers in earlier lines: Several Phase II studies examined CD3×CD20 or CD3×BCMA constructs in second-line follicular lymphoma and first-line multiple myeloma, showing better tolerability than earlier-line CAR T but trade-offs in durable remission duration.
• Perioperative IO–chemo combinations: At least two randomized Phase III trials in gastric and esophageal cancer added a PD-1 inhibitor to neoadjuvant chemo, reporting improvements in pathologic complete response (pCR) rates of 12–18% absolute gain, with survival follow-up still immature.
• ctDNA-adapted trial designs: More mid-year readouts used longitudinal circulating tumor DNA to trigger treatment intensification or de-escalation, moving beyond traditional radiographic endpoints.

Background: How We Got Here

Oncology trial design has shifted substantially over the past five years. The maturation of immune checkpoint blockade in adjuvant and neoadjuvant settings created a foundation for combination strategies now reaching Phase III readout. Concurrently, the accelerated approval pathway has produced a dense landscape of targeted agents—many for small biomarker-defined subsets—creating pressure to demonstrate superiority or safety over existing options in confirmatory trials. The 2025 mid-year data reflect this crowded environment, where incremental gains in progression-free survival (often 2–4 months) must be weighed against added cost and toxicity.

Stakeholder Concerns and Practical Tensions

Clinicians, patients, and payers are responding to these updates with a set of recurring questions:

• Sequencing uncertainty: When an ADC or bispecific agent shows activity post-platinum, does it slot better before or after a checkpoint inhibitor? Mid-year data rarely provide cross-trial answers, forcing real-world extrapolation.
• Financial toxicity of multi-drug regimens: Adding a novel agent to an existing SOC backbone can raise monthly out-of-pocket costs by 30–50% for insured patients, depending on coverage and copay caps.
• Representation gaps: Several mid-2025 trials enrolled fewer than 15% of patients over age 75 or with ECOG PS 2, limiting generalizability to the average community oncology population.
• Patient preference for quality of life: Grade 3+ adverse events with novel combinations (e.g., ADC-related ocular or pulmonary toxicity) are prompting greater inclusion of patient-reported outcomes in later-phase studies, but these data were often not yet mature at mid-year disclosures.

Likely Impact on Clinical Practice

While full guideline integration requires regulatory decisions and peer-reviewed publication, some mid-2025 signals are expected to influence clinical decisions in the near term:

• Expanded neoadjuvant options: In HER2-negative, PD-L1–positive early breast cancer, an IO–chemo combination showing a pCR benefit of ~15% is likely to become a preferred regimen for high-risk patients pending overall survival data.
• Backbone replacement in advanced GC/GEJ: A TROP2-directed ADC may begin to replace paclitaxel as the standard second-line option if confirmatory data hold, based on a response rate advantage of 8–10% and a favorable neuropathy profile.
• Tighter biomarker stratification: Mid-2025 results reinforce the use of NGS-based tumor mutational burden (TMB) and homologous recombination deficiency (HRD) scores as enrichment strategies—trials that pre-selected these groups showed effect sizes roughly double those of all-comer designs.
• Treatment holidays in myeloma: Updated data on fixed-duration versus continuous therapy with bispecific antibodies suggest that stopping after 12–18 months in responders may reduce infection risk without immediate loss of disease control in approximately 70–80% of patients.

What to Watch Next (Second Half of 2025)

Several highly anticipated readouts remain pending:

• Adjuvant targeted therapy in NSCLC: Phase III results of a next-generation EGFR TKI against osimertinib in resected Stage IB–IIIA disease, with central nervous system recurrence as a key endpoint.
• First-line CAR T in large B-cell lymphoma: Updated enrollment and early response data from a study randomizing patients to CAR T versus standard chemoimmunotherapy in first-line high-risk disease.
• Vaccine-based combination trials: Personalized neoantigen vaccines plus checkpoint blockade in resected pancreatic cancer versus observation alone, with the first disease-free survival interim analysis expected.
• Policy and access decisions: FDA and EMA actions on several of the agents highlighted at mid-year, especially those seeking expanded approval beyond the initial accelerated indication.

Summary: The mid-2025 oncology update shows steady progress in ADCs, bispecifics, and perioperative strategies, but also highlights real-world gaps in sequencing evidence, cost considerations, and patient representation. The second half of the year will clarify which of these advances truly shift the standard of care.